加载中
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
收盘时
US$2.50
+US$0.01 · +0.40%
盘后
US$2.50
US$0.00 · 0.00%
10月13日 16:16 ET
盘中时间采用ET。市场数据可能有所延迟。
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
日内区间
当前US$2.50
52周区间
当前US$2.50
盘中时间采用ET。市场数据可能有所延迟。
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
日内区间
当前US$2.50
52周区间
当前US$2.50
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 139.7万 USD | 150.5万 USD | 118.4万 USD | — | — |
| 毛利 | −139.7万 USD | −150.5万 USD | −118.4万 USD | — | — |
| 研究与开发 | 7104.3万 USD | 7647.8万 USD | 6812.6万 USD | 5407.7万 USD | 2379.9万 USD |
| 销售、一般及管理费用 | 2256.9万 USD | 2126.1万 USD | 1664万 USD | 1422.4万 USD | 811万 USD |
| 营业费用 | 9221.5万 USD | 9623.4万 USD | 8358.2万 USD | 6830.1万 USD | 2710.9万 USD |
| 利息收入 | 401.7万 USD | 714.2万 USD | 640万 USD | 279.3万 USD | — |
| 折旧和摊销 | 139.7万 USD | 150.5万 USD | 118.4万 USD | 49.3万 USD | 17.8万 USD |
| 营业利润 | −9361.2万 USD | −9773.9万 USD | −8476.6万 USD | −6830.1万 USD | −2710.9万 USD |
| 净利润 | −8965.5万 USD | −8998.1万 USD | −7862.6万 USD | −6910.4万 USD | −2728.1万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$4.00
上涨空间 60.00%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI421.13万0.00%2.3万亿 USD0.03%US$381.32-0.07%
Vanguard Extended Market ETFVXF156.08万0.00%954亿 USD0.05%US$232.54-0.42%
iShares Biotechnology ETFIBB123.15万0.01%108.2亿 USD0.44%US$200.02-2.08%
iShares Micro-Cap ETFIWC33.21万0.03%13.17亿 USD0.60%US$179.6-1.13%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM21万0.18%1.16亿 USD0.73%US$15.6501-1.25%
Avantis U.S. Small Cap Equity ETFAVSC10.85万—30.79亿 USD0.25%US$70.06+0.13%
Dimensional - US Small Cap ETFDFAS5.52万0.00%338.04亿 USD0.31%US$78.33+0.20%
U.S. Vector Equity Portfolio ETF Class SharesDXUV5.03万0.00%61.96亿 USD0.26%US$68.51+0.28%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAvantis U.S. Small Cap Equity ETFAVSCDimensional - US Small Cap ETFDFASU.S. Vector Equity Portfolio ETF Class SharesDXUVAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
